Expression of immune checkpoints in T cells of esophageal cancer patients

Oncotarget

Volumn 7, Issue 39, 2016, Pages 63669-63678

  Jinhua, Xie ^a   Ji, Wang ^b   Shouliang, Cheng ^a   Liangfeng, Zheng ^a   Feiyue, Ji ^a   Lin, Yang ^b   Yan, Zhang ^a   Haoming, Ji ^a  

^a NANTONG UNIVERSITY   (China)

^b SOOCHOW UNIVERSITY   (China)

Author keywords

Cancer immunotherapy; Esophageal cancer; Immune checkpoints; PD 1; TIM 3

Indexed keywords

CD137 ANTIGEN; CD137 LIGAND; CD158 PROTEIN; CD160 PROTEIN; CD200 ANTIGEN; CD27 ANTIGEN; CD28 ANTIGEN; CELL PROTEIN; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; IMMUNE CHECKPOINT PROTEIN; LYMPHOCYTE ANTIGEN; MEMBRANE PROTEIN; PROGRAMMED DEATH 1 RECEPTOR; T CELL IG AND ITIM DOMAIN PROTEIN; T CELL IMMUNOGLOBULIN MUCIN 3 PROTEIN; UNCLASSIFIED DRUG; HAVCR2 PROTEIN, HUMAN; HEPATITIS A VIRUS CELLULAR RECEPTOR 2; IMMUNOGLOBULIN RECEPTOR; PDCD1 PROTEIN, HUMAN; TIGIT PROTEIN, HUMAN;

AGED; ANTIGEN EXPRESSION; ARTICLE; CANCER PATIENT; CD4+ T LYMPHOCYTE; CELL STRESS; CELLULAR DISTRIBUTION; CLINICAL ARTICLE; CLINICAL FEATURE; CONTROLLED STUDY; ESOPHAGUS CANCER; FEMALE; HUMAN; HUMAN CELL; MALE; PERIPHERAL LYMPHOCYTE; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; PROTEIN TARGETING; T LYMPHOCYTE; TUMOR ASSOCIATED LEUKOCYTE; UPREGULATION; CASE CONTROL STUDY; CD8+ T LYMPHOCYTE; CELL CYCLE CHECKPOINT; ESOPHAGUS TUMOR; GENE EXPRESSION REGULATION; GENETICS; IMMUNE SYSTEM; IMMUNOLOGY; IMMUNOTHERAPY; LYMPHOCYTE ACTIVATION; METABOLISM; MIDDLE AGED; PHYSIOLOGY;

AGED; CASE-CONTROL STUDIES; CD8-POSITIVE T-LYMPHOCYTES; CELL CYCLE CHECKPOINTS; CTLA-4 ANTIGEN; ESOPHAGEAL NEOPLASMS; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HEPATITIS A VIRUS CELLULAR RECEPTOR 2; HUMANS; IMMUNE SYSTEM; IMMUNOTHERAPY; LYMPHOCYTE ACTIVATION; LYMPHOCYTES, TUMOR-INFILTRATING; MALE; MIDDLE AGED; PROGRAMMED CELL DEATH 1 RECEPTOR; RECEPTORS, IMMUNOLOGIC; T-LYMPHOCYTES; UP-REGULATION;

EID: 84993990731     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.11611     Document Type: Article

References (15)

1. Rustgi AK, El-Serag HB. Esophageal Carcinoma. N Engl J Med. 2014; 371:2499-2509.
2. Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer. 2012; 12:252-264.
3. Nirschl CJ, Drake CG. Molecular pathways: coexpression of immune checkpoint molecules: signaling pathways and implications for cancer immunotherapy. Clin Cancer Res. 2013; 19:4917-4924.
4. Sondak VK, Smalley KSM, Kudchadkar R, Grippon S, Kirkpatrick P. Ipilimumab. Nat Rev Drug Discov. 2011; 10:411-412.
5. Suzanne LT, Hodi FS, Julie RB, Scott NG, David CS, David FM, John DP, Richard DC, Jeffrey AS, Michael BA, Philip DL, David RS, Scott JA, et al. Safety, Activity, and Immune Correlates of Anti-PD-1 Antibody in Cancer. N Engl J Med. 2012; 366.
6. Derks S, Nason KS, Liao X, Stachler MD, Liu KX, Liu JB, Sicinska E, Goldberg MS, Freeman GJ, Rodig SJ, Davison JM, Bass AJ. Epithelial PD-L2 expression marks Barrett's Esophagus and Esophageal Adenocarcinoma. Cancer Immunol Res. 2015.
7. Joller N, Hafler JP, Brynedal B, Kassam N, Spoerl S, Levin SD, Sharpe AH, Kuchroo VK. Cutting edge: TIGIT has T cell-intrinsic inhibitory functions. J Immunol. 2011; 186:1338-1342.
8. Lozano E, Dominguez-Villar M, Kuchroo V, Hafler D. The TIGIT/CD226 axis regulates human T cell function. J Immunol. (Baltimore, Md: 1950). 2012; 188:3869-3875.
9. Fourcade J, Sun Z, Benallaoua M, Guillaume P, Luescher IF, Sander C, Kirkwood JM, Kuchroo V, Zarour HM. Upregulation of Tim-3 and PD-1 expression is associated with tumor antigen-specific CD8+ T cell dysfunction in melanoma patients. J Exp Med. 2010; 207:2175-2186.
10. Zhou Q, Munger M, Veenstra R, Weigel B, Hirashima M, Munn D, Murphy W, Azuma M, Anderson A, Kuchroo V, Blazar B. Coexpression of Tim-3 and PD-1 identifies a CD8+ T-cell exhaustion phenotype in mice with disseminated acute myelogenous leukemia. Blood. 2011; 117:4501-4510.
11. Chauvin JM, Pagliano O, Fourcade J, Sun Z, Wang H, Sander C, Kirkwood JM, Chen TH, Maurer M, Korman AJ, Zarour HM. TIGIT and PD-1 impair tumor antigen-specific CD8(+) T cells in melanoma patients. J Clin Invest. 2015; 125:2046-2058.
12. Johnston RJ, Comps-Agrar L, Hackney J, Yu X, Huseni M, Yang Y, Park S, Javinal V, Chiu H, Irving B, Eaton DL, Grogan JL. The immunoreceptor TIGIT regulates antitumor and antiviral CD8(+) T cell effector function. Cancer Cell. 2014; 26:923-937.
13. Wei F, Zhong S, Ma Z, Kong H, Medvec A, Ahmed R, Freeman GJ, Krogsgaard M, Riley JL. Strength of PD-1 signaling differentially affects T-cell effector functions. Proc Natl Acad Sci USA. 2013; 110:E2480-2489.
14. Yan J, Zhang Y, Zhang J-P, Liang J, Li L, Zheng L. Tim-3 expression defines regulatory T cells in human tumors. PloS one. 2013; 8.
15. D'Incecco A, Andreozzi M, Ludovini V, Rossi E, Capodanno A, Landi L, Tibaldi C, Minuti G, Salvini J, Coppi E, Chella A, Fontanini G, Filice ME, et al. PD-1 and PD-L1 expression in molecularly selected non-small-cell lung cancer patients. Br J Cancer. 2015; 112:95-102.